Fortress Biotech Inc
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe reca… Read more
Fortress Biotech Inc (FBIO) - Total Assets
Latest total assets as of September 2025: $181.41 Million USD
Based on the latest financial reports, Fortress Biotech Inc (FBIO) holds total assets worth $181.41 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fortress Biotech Inc - Total Assets Trend (2009–2024)
This chart illustrates how Fortress Biotech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Fortress Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Fortress Biotech Inc's total assets of $181.41 Million consist of 62.7% current assets and 37.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.7% |
| Accounts Receivable | $10.40 Million | 7.2% |
| Inventory | $14.43 Million | 10.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $31.86 Million | 22.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Fortress Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fortress Biotech Inc's current assets represent 62.7% of total assets in 2024, a decrease from 89.8% in 2009.
- Cash Position: Cash and equivalents constituted 39.7% of total assets in 2024, down from 89.5% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 22.1% of total assets.
Fortress Biotech Inc Competitors by Total Assets
Key competitors of Fortress Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Fortress Biotech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Fortress Biotech Inc generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Fortress Biotech Inc is currently not profitable relative to its asset base.
Fortress Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.19 | 1.23 | 5.14 |
| Quick Ratio | 1.97 | 1.06 | 5.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $64.44 Million | $ 15.97 Million | $ 214.39 Million |
Fortress Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Fortress Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.04 |
| Latest Market Cap to Assets Ratio | 0.51 |
| Asset Growth Rate (YoY) | -13.9% |
| Total Assets | $144.22 Million |
| Market Capitalization | $73.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values Fortress Biotech Inc's assets below their book value (0.51 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Fortress Biotech Inc's assets decreased by 13.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Fortress Biotech Inc (2009–2024)
The table below shows the annual total assets of Fortress Biotech Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $144.22 Million | -13.91% |
| 2023-12-31 | $167.53 Million | -43.08% |
| 2022-12-31 | $294.30 Million | -25.78% |
| 2021-12-31 | $396.50 Million | +18.92% |
| 2020-12-31 | $333.41 Million | +47.25% |
| 2019-12-31 | $226.42 Million | +60.59% |
| 2018-12-31 | $140.99 Million | -42.67% |
| 2017-12-31 | $245.95 Million | +44.06% |
| 2016-12-31 | $170.73 Million | +43.94% |
| 2015-12-31 | $118.61 Million | +32.78% |
| 2014-12-31 | $89.33 Million | -11.19% |
| 2013-12-31 | $100.58 Million | +145.37% |
| 2012-12-31 | $40.99 Million | +75.37% |
| 2011-12-31 | $23.38 Million | +56.47% |
| 2010-12-31 | $14.94 Million | +785.54% |
| 2009-12-31 | $1.69 Million | -- |